Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Aclaris Therapeutics

• The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 352,397 shares at an average price of $1.15. To acquire these shares, it cost around $405,894.
• What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
• What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

RENN Fund

• The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 184 shares at an average price of $1.74. To acquire these shares, it cost around $320.
• What's Happening: RENN Fund shares rose around 5% over the past month.
• What RENN Fund Does: RENN Fund Inc is active in the financial services domain.

Check This Out: Top 3 Financial Stocks You’ll Regret Missing In Q3